The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer/Onyx; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer
Bernard J. Escudier
Consultant or Advisory Role - Bayer/Onyx; Novartis; Pfizer
Honoraria - AVEO; Bayer/Onyx; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche (I)
Thomas Powles
Consultant or Advisory Role - Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline
David Cella
Consultant or Advisory Role - AVEO; Bayer; Exelixis; Novartis; Pfizer
Research Funding - AVEO; Bayer; Novartis; Pfizer
Qinhua C. Ru
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis (B)
Christian Scheffold
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Robert J. Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Exelixis; GlaxoSmithKline; Novartis; Pfizer
Expert Testimony - Pfizer